Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

MedImmune Licenses Engineered Proteases

by Rick Mullin
July 13, 2009 | A version of this story appeared in Volume 87, Issue 28

Catalyst Biosciences has signed a research and licensing agreement with AstraZeneca's MedImmune biologics unit to develop novel engineered proteases that degrade or modulate two disease targets, one of which has been identified as an inflammatory and autoimmune disease target. Catalyst will receive an undisclosed up-front licensing fee, full-time employee support, and development milestone payments up to $195 million, in addition to royalties for commercialized drugs. MedImmune will be responsible for late-stage development, manufacturing, and commercialization of products discovered in the collaboration.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.